4:53 PM
 | 
Mar 07, 2018
 |  BC Extra  |  Company News

Eisai, Merck in global oncology deal

Eisai Co. Ltd. (Tokyo:4523) and Merck & Co. Inc. (NYSE:MRK) partnered worldwide to jointly develop and commercialize Eisai's cancer drug Lenvima lenvatinib mesylate as monotherapy and in combination with PD-1 mAb Keytruda pembrolizumab to treat cancer. The combination is being evaluated in the Phase III Study 307 trial to...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >